Full Text
PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

Abstract

Authors

C Peral M Valderrama M Montoro S Gomez M Tarallo

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×